ACE and hypertensive disorder: The BP lowering achieved in response to riboflavin occurred despite a major change in the UK clinical guidelines for the management of hypertension during the four-year follow-up period, resulting in a shift from monotherapy to polytherapy, thus additional medications being prescribed, and a change from β-blockers to angiotensin-converting enzyme (ACE) inhibitors as the drugs of first choice [7].